BioMap focuses on leveraging artificial intelligence (AI) to advance life sciences. The company develops AI Foundation Models to understand and predict complex biological behaviors and creates task models for various life science applications, including therapeutic antibodies and industrial enzymes. BioMap primarily serves the biotechnology and pharmaceutical industries with its AI-driven solutions. It was founded in 2020 and is based in Palo Alto, California.
BioMap's Products & Differentiators
Research containing BioMap
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned BioMap in 2 CB Insights research briefs, most recently on Feb 14, 2024.
Expert Collections containing BioMap
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
BioMap is included in 4 Expert Collections, including Artificial Intelligence.
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Drug Discovery Tech Market Map
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
Early-Stage Pharma Market Map
Latest BioMap News
Dec 23, 2023
publication date: Dec 23, 2023 | Deals and Financings GSK acquired ex-Greater China rights to a second ADC from Jiangsu’s Hansoh Pharma in a $1.7 billion agreement (see story ). GSK’s latest acquisition, HS-20093, is a B7-H3 targeted antibody-drug conjugate (ADC) with a topoisomerase inhibitor (TOPOi) payload that is in China Phase I/II trials for solid tumor cancers. Hansoh will receive $185 million upfront and up to $1.525 billion in milestones, plus royalties. Two months ago, GSK announced a $1.6 billion deal for Hansoh’s B7-H4 ADC that has started a Phase I China trial for gynecologic cancers. Boston’s Nona Biosciences out-licensed global rights for its MSLN-targeted ADC to Pfizer for $53 million in upfront and near-term payments and $1 billion in potential milestones (see story ). It is also eligible for tiered royalties. HBM9033 targets MSLN, a tumor-associated antigen upregulated in mesothelioma, ovarian, lung, breast and pancreatic cancers. Nona is a wholly owned subsidiary of Harbour BioMed, a Boston-Rotterdam-Shanghai company that uses its Harbour Mice® antibody technology platform to generate fully human monoclonal antibodies. Nona’s candidate was developed in collaboration with MediLink Therapeutics, a Boston-Suzhou ADC biotech. Suzhou CStone Pharma sold China-Singapore commercialization rights for Tibsovo® (ivosidenib tablets) to Servier of Paris for $50 million (see story ). CStone originally acquired the China rights to the drug from Agios Pharmaceuticals, which subsequently became part of Servier. Tibsovo is an oral targeted IDH1 inhibitor that is approved in China to treat adult patients with relapsed/refractory acute myeloid leukemia with an IDH1 mutation. CStone said the sale would save paying additional milestones while it recouped its investment. In 2018, CStone in-licensed the rights in a $424 million deal, though it paid only $12 million upfront plus $147 million in milestones. Huadong Medicine will collaborate with Shanghai’s Impact Therapeutics to promote Impact’s Senaparib, a novel PARP inhibitor, in mainland China (see story ). Impact will receive $14 million upfront and up to $26 million in milestones. Huadong will receive promotion service fees on net sales. Impact will continue to be responsible for development, registration, manufacturing, supply and distribution of Senaparib. Earlier this year, Impact announced Senaparib met its primary endpoint in a China Phase III trial as a maintenance therapy for ovarian cancer following first-line platinum-based chemotherapy. Impact develops oncology medicines based on synthetic lethality. Suzhou GeneQuantum Healthcare (GQ), an ADC company, formed a collaboration with Beijing’s BioMap, an AI-based startup that analyzes the sequence and structure of proteins, to co-develop FIC/BIC ADC therapeutics for multiple targets (see story ). GQ will use its proprietary enzymatic site-specific conjugation technology platforms (iLDC® and iGDC®) along with its linker-payload platform. BioMap will contribute its life science AI Foundation Large Language Model xTrimo and AI protein generation platform, AIGP. Two months ago, BioMap announced a drug discovery deal worth up to $1 billion with Sanofi. Zhejiang Ablaze Medicine, a Hangzhou company that provides services for clinical trials, formed a partnership with Singapore’s Oncoshot, a company applying AI to streamline clinical trials (see story ). Recently, Ablaze has expanded into data management and clinical trials recruitment. Oncoshot offers data analysis and insights that improve clinical trials. Together, the two companies expect to use AI to transform the speed, efficiency and accessibility of global drug development programs. After 20 years of aiding clinical trials, Ablaze now facilitates over 200 global customers across four continents to optimize research outcomes. Nanjing InxMed licensed rights to use an EZWi-Fit® linker-payload platform developed by Shanghai’s Escugen to develop ADCs containing next-gen tumor-associated antigens (see story ). InxMed, a company that develops innovative therapies to counteract drug resistance, will apply Escugen’s platform to several novel ADC candidates. The company believes its next-gen ADCs will have better tumor selectivity and greater potency, allowing the possibility of combinations with other candidates. InxMed will have the right for development, manufacturing and commercialization of the ADC candidates. Beijing Biocytogen Pharma entered an agreement allowing Barcelona’s Ona Therapeutics to evaluate Biocytogen’s proprietary RenMice®-derived fully human antibodies against a specific tumor target (see story). Ona will have an option to acquire an exclusive license to the antibodies for development, manufacturing and commercialization of an antibody-drug conjugate. Biocytogen will receive an upfront payment for the option, and it will be eligible to receive an option-exercise fee, milestone payments and royalties. Based on its gene editing technology, Biocytogen uses its genetically engineered proprietary platforms to discover novel drug candidates. http://www.chinabiotoday.com/articles/biocytogen-adc-ona Trials and Approvals CellOrigin Biotechnology (Hangzhou) announced a solid-tumor patient was dosed in a China trial of SY001, the first China trial of a CAR-macrophage therapy (see story ). The company develops immune cell therapies (such as macrophages, NK cells) derived from genetically engineered pluripotent stem cells (iPSC) for solid tumor cancers. It believes the unique characteristics of macrophages allow the drug to infiltrate the solid tumor microenvironment. In the first two patients, SY001 was well tolerated with no dose-limiting toxicity. The investigator-led study is enrolling patients with advanced solid tumors. RNAimmune announced it was authorized to start US Phase I trials of RV-1770, an mRNA vaccine aimed at Respiratory Syncytial Virus (see story ). A subsidiary of Sirnaomics, RNAimmune is a Maryland-Guangzhou company that develops mRNA-based therapeutics and vaccines. RV-1770 is a novel mRNA-based vaccine formulation with a unique AI-enhanced design based on the sequence of the recent RSV clinical isolate. The candidate is a combination of an mRNA-based vaccine with a proprietary lipid nanoparticle formulation, aimed at preventing RSV infection in adults. RNAimmune is focused on developing products for infectious diseases, cancer and rare diseases. Disclosure: none.
BioMap Frequently Asked Questions (FAQ)
When was BioMap founded?
BioMap was founded in 2020.
Where is BioMap's headquarters?
BioMap's headquarters is located at 2460 Embarcadero Way, Palo Alto.
What is BioMap's latest funding round?
BioMap's latest funding round is Series A.
How much did BioMap raise?
BioMap raised a total of $100M.
Who are the investors of BioMap?
Investors of BioMap include Lanchi Ventures, Jiyuan Venture Capital, Legend Capital, Baidu, Xiang He Capital and 4 more.
Who are BioMap's competitors?
Competitors of BioMap include Brightseed and 8 more.
What products does BioMap offer?
BioMap's products include BP-001 and 4 more.
Compare BioMap to Competitors
Atomwise develops machine learning-based discovery engines and uses deep learning and artificial intelligence (AI)-based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions and designs drugs using computational drug design. The company was founded in 2012 and is based in San Francisco, California.
Standigm is an AI-driven drug discovery company operating in the pharmaceutical industry. The company's main services include the use of proprietary AI platforms for novel target identification, lead generation, and the creation of commercially valuable drug pipelines. Standigm primarily sells to the pharmaceutical and healthcare industries. It was founded in 2015 and is based in Seoul, South Korea.
Healx provides drug discovery services. The company manufactures drugs using technology to bring treatments for rare diseases to patients. Its platform, Healnet, helps face challenges by analyzing drug and disease data points. The company was founded in 2014 and is based in Cambridge, U.K.
Aria Pharmaceuticals is a preclinical-stage pharmaceutical company that focuses on the discovery and development of novel, small molecule therapies in the pharmaceutical industry. The company's main service is the development of new treatments for complex and hard-to-treat diseases using their proprietary Symphony platform, which combines biomedical data and artificial intelligence to increase the success rates of drug discovery. Aria Pharmaceuticals primarily serves the healthcare sector, specifically targeting areas where new therapies are most needed. It was founded in 2014 and is based in Palo Alto, California.
Aitia is a company focused on the development and application of Causal AI and Digital Twins in the pharmaceutical industry. The company's main services include the discovery of drugs for neurodegenerative disorders, oncology, and immunology by revealing hidden biological mechanisms of diseases and creating Digital Twins. These Digital Twins are used to discover novel therapies and accelerate research and development in various diseases such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, multiple myeloma, prostate cancer, and pancreatic cancer. It was founded in 2000 and is based in Cambridge, Massachusetts.
XtalPi provides quantum physic-based artificial intelligence (AI) for drug research and development. It offers accurate predictions on the physicochemical and pharmaceutical properties of small-molecule candidates for drug design, solid-form selection, and other critical aspects of drug development. XtalPi was founded in 2014 and is based in Shenzhen, China.